Results 101 to 110 of about 126,534 (277)

Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]

, 2019
The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K, Cabrales, Pedro, Lee, Yun Sok, Riopel, Matthew   +3 more
core  

Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. [PDF]

, 2016
Glucagon is one of the main regulators of blood glucose levels and dysfunctional stimulus secretion coupling in pancreatic A-cells is believed to be an important factor during development of diabetes.
Ahlstedt, I., Elhachmane, M., Gopel, S., Pedersen, MORTEN GRAM   +3 more
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Journal of Pharmaceutical Policy and Practice
Background High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot
Michael J. DiStefano, Mouna Dardouri, Gina D. Moore, Joseph J. Saseen, Kavita V. Nair   +4 more
doaj   +1 more source

Glucagon-Like Peptide-1 Modulates Neurally-Evoked Mucosal Chloride Secretion in Guinea Pig Small Intestine In Vitro. [PDF]

, 2011
Glucagon-like peptide-1 (GLP-1) acts at the G protein-coupled receptor, GLP-1R, to stimulate secretion of insulin and to inhibit secretion of glucagon and gastric acid. Involvement in mucosal secretory physiology has received negligible attention. We
BALDASSANO, Sara, MULE', Flavia, Wang, GD, Wood, JD   +3 more
core   +1 more source

Beyond right or wrong: How partial credit scoring on multiple‐choice questions improves student performance and assessment perceptions

British Journal of Clinical Pharmacology, EarlyView.
Aims In this study, we examined the effects of assigning partial credit to selected answer choices on student performance and perceptions in a pharmacology course using Type A multiple‐choice questions (MCQs). Methods Partial credit scoring was incorporated into quizzes and exams in a 10‐week pharmacology course for postbaccalaureate premedical ...
Stephen D. Schneid, Chris Armour, Katharina Brandl   +2 more
wiley   +1 more source

Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells [PDF]

, 2012
Peer reviewedPublisher ...
A Kubo, AK Teo, C. H.-H. Cho, D Zhang, E Kroon, E Wandzioch, F. M. Docherty, H Li, H. M. Docherty, IG Brons, J Ameri, J Cai, J Jonsson, JA Thomson, JF Habener, JK Mfopou, JM Wells, JR Spence, K Takahashi, K. Docherty, KA D’Amour, KA Harrison, KS Zaret, L Vallier, L Vallier, L. Vallier, M Inamura, M Polak, M. Joåo Lima, M. W. B. Trotter, MC Nostro, MF Offield, N. R.-F. Hannan, OG Kelly, R Bort, R Maehr, RI Sherwood, S Brown, ST Rashid, T Touboul, V Ramos-Mejia, W Jiang, Y Kunisada   +42 more
core   +2 more sources

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]

Electronic Physician, 2013
:Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes.Methods: This was a quasi-experimental study. The population was consisted
Roja Daliri, Sara Heidarzadeh, Parvin Farzanegi, Mohammad Ali Azarbayjani   +3 more
doaj  

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans [PDF]

, 2006
Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying.Aims: To assess the effects of endogenous GLP-1 on endocrine pancreatic ...
Göke, Burkhard, Katschinski, M., Nicolaus, Mathias, Roggel, R., Schirra, Joerg, Storr, Martin, Woerle, H. J.   +6 more
core   +2 more sources